Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | RGS2 |
| Gene Name: | RGS2 |
| Protein Full Name: | Regulator of G-protein signaling 2 |
| Alias: | Cell growth-inhibiting 31; G0 to G1 switch regulatory 8, 24kD; G0/G1 switch regulatory 8; G0S8; Regulator of G-protein signaling 2, 24kDa; Regulator of G-protein signalling 2, 24kDa |
| Mass (Da): | 24382 |
| Number AA: | 211 |
| UniProt ID: | P41220 |
| Locus ID: | 5997 |
| COSMIC ID: | RGS2 |
| Gene location on chromosome: | 1q31.2 |
| Cancer protein type: | UNCLEAR |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | UNCLEAR |
| Number of cancer specimens: | 19717 |
| Percent of cancer specimens with mutations: | 0.14 |
| Normal role description: | RGS2 functions as a regulator of G protein signalling by acting as GTPase activating protein for the α subunit of heterotrimeric G proteins (Gi, Go and Gq). RGS2 acts as a mediator of myeloid differentiation and may play a role in leukemogenesis. It is also involved in the negative feedback control pathway for adenylyl cyclase signalling, and has been found to bind EIF2B5 and to block its activity, hence leading to inhibition of the translation of mRNA into protein. The gene has been found to be either up- or down-regulated in a number of cancers, but no causal relationships between it and cancer development have been found. |